Publicaciones en colaboración con investigadores/as de Medical University of Vienna (14)

2024

  1. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2023

  1. GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

    Cell Reports Medicine, Vol. 4, Núm. 12

2022

  1. Current practice in proton therapy delivery in adult cancer patients across Europe

    Radiotherapy and Oncology, Vol. 167, pp. 7-13

  2. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2021

  1. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190

  2. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    Radiotherapy and Oncology, Vol. 154, pp. 327-353

  3. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39

  4. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2018

  1. Safety and dose modification for patients receiving niraparib

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792

2016

  1. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

  2. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT- GCIG intergroup study (HECTOR)

    Annals of Oncology, Vol. 27, Núm. 12, pp. 2236-2241

2013

  1. Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

    Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8

2006

  1. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

    Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284